Point-of-Care Infectious Disease Diagnostics/Testing Market 2014-2025 – Analysis by Disease, End-use and Segment Forecasts

Dublin, Sept. 25, 2017 (GLOBE NEWSWIRE) -- The "Point-of-Care Infectious Disease Diagnostics/Testing Market Analysis by Disease (HIV POC, HBV POC, Influenza/Flu POC, TB & drug-resistant TB POC), by End-use and Segment Forecasts, 2014 - 2025" report has been added to Research and Markets' offering.

The global point-of-care infectious disease diagnostics/testing market is expected to reach USD 1.90 billion by 2025. The emerging trend of patient-centric services coupled with escalating incidence rates of complicated infectious disorders is expected to upsurge the demand for portable and accurate detection devices, thus resulting in market growth. The potential in these devices to enable rapid detection of infectious diseases is attributive for the estimated market.

Moreover, revolutionizing patient care brought about by these devices is responsible for the rising demand for decentralized testing settings. Rise in the investments for R&D and development of new products is expected to spur progress in this market through to 2025.

For instance, development of a new lab-on-a-disc' technology developed by an EU project research team aids in the diagnosis of different infectious diseases including malaria. It enables faster diagnosis as a consequence of implementation of point-of-care treatment. This allows precise drugs administration thus influencing adoption rate.

Further key findings from the report suggest:

  • HIV POC is estimated to account for the largest share owing to the rising incidence of this disease
  • Advances in the bio sensing technology for the early detection with sensitivity is expected to fuel revenue generation in the coming years
  • Moreover, companies are engaged in embracing a quality management approach for the introduction of novel tests for HIV diagnosis
  • TB and drug resistant TB is anticipated to witness lucrative demand in the coming years as a result of rise in the incidence rate of drug resistance TB
  • Demand for the development of inexpensive, rapid, simple, and accurate tests that are able to detect multiple biomarkers simultaneously is expected to boost progress
  • Implementation of fully or partially integrated nano/microscale technologies in developing DR-TB diagnostic devices is anticipated to fuel progress in the segment
  • Clinics accounted for the largest revenue share owing to the higher usage of rapid testing kits in clinics
  • North America dominates the space with adequate administration support, well-established healthcare framework, and extensive research & technology upgradation
  • Asia Pacific region is expected to showcase the fastest growth over the forecast period due to rising incidence and prevalence rates of infectious diseases with suitable government support
  • The major players in the sector include Siemens Healthineers, Trivitron Healthcare, F. Hoffmann-La Roche Ltd, Alere, Quest Diagnostics, Inc, BD & Company, Chembio Diagnostics Inc,Trinity Biotech, Cardinal Health,Bio-Rad Labs Inc.,bioMrieux SA, Thermo Fisher Scientific Inc, Sight Diagnostics Ltd.,Gene POC, Ortho-Clinical Diagnostics, and OJ-Bio Ltd.

Key Topics Covered:

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Point -of- Care Infectious Disease Diagnostics/Testing Market: Variables, Trends & Scope

Chapter 4 Point -of- Care Infectious Disease Diagnostics/Testing: Disease Estimates & Trend Analysis

Chapter 5 Point -of- Care Infectious Disease Diagnostics/Testing: End-Use Estimates & Trend Analysis

Chapter 6 Point -of- Care Infectious Disease Diagnostics/Testing: Regional Estimates & Trend Analysis by Disease, & End-Use

Chapter 7 Competitive Landscape

  • Alere
  • BD & Company
  • Cardinal Health,Bio-Rad Labs Inc.,bioMrieux SA
  • Chembio Diagnostics Inc,Trinity Biotech
  • F. Hoffmann-La Roche Ltd
  • OJ-Bio Ltd
  • Ortho-Clinical Diagnostics
  • Quest Diagnostics Inc
  • Siemens Healthineers
  • Sight Diagnostics Ltd.,Gene POC
  • Thermo Fisher Scientific Inc
  • Trivitron Healthcare

For more information about this report visit https://www.researchandmarkets.com/research/f7sw5p/pointofcare


CONTACT: 


CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Point-of-Care Diagnostics, Infectious Disease Testing

Ads